融合タンパク質の2030年までの市場予測：タイプ別、用途別、地域別の世界分析

Stratistics MRCによると、世界の融合タンパク質市場は2023年に298億米ドルを占め、予測期間中のCAGRは6.2％で成長し、2030年には454億米ドルに達すると予測されています。

融合タンパク質は、別々のタンパク質をコードする2つ以上の遺伝子を結合することで作られる人工タンパク質です。これらのハイブリッドタンパク質は、バイオテクノロジーや医療など様々な用途に用いられます。バイオテクノロジーでは、融合タンパク質は研究や治療目的で特定のタンパク質を大量に生産するために使用されます。また、タンパク質精製のための分子タグとして、あるいはタンパク質の相互作用を研究するためのツールとして利用されることもあります。

Globocan 2020によると、新たに報告されたがんの症例数は19,292,789件で、この数は2040年までに28,887,940件に増加すると予想されています。

慢性疾患の増加

コンテンツや配信チャネルのデジタル化が進むにつれ、ハッキング、データ侵害、不正配信などのサイバー脅威から貴重な知的財産を保護する必要性が高まっています。DRMソリューションは、強固な暗号化、アクセス制御、監視機能を提供し、サイバー犯罪者が機密コンテンツを侵害したり盗んだりすることを困難にします。その結果、エンターテインメント、出版、ソフトウェア開発などの業界では、自社の資産を保護するためにDRMテクノロジーの採用が増加しており、コンテンツのセキュリティを確保し、サイバー攻撃や海賊行為による収益損失のリスクを低減しています。

高い開発コスト

融合タンパク質療法を市場に送り出すために必要な研究開発および臨床試験には、多額の資金が必要となります。これらのコストには、前臨床試験、大規模な臨床試験、規制への対応、製造インフラなどが含まれます。高い開発費は、中小のバイオテクノロジー企業にとっては特に困難であり、技術革新と競争力を制限する可能性があります。このような制約を克服するためには、共同研究、官民パートナーシップ、資金援助イニシアティブが、融合タンパク質の研究開発を支援するために不可欠です。さらに、費用対効果の高い開発戦略と効率的な臨床試験デザインは、この経済的負担を軽減し、最終的にこの重要な治療分野の成長を促進するのに役立ちます。

ドラッグデリバリー技術の向上

ナノ粒子、リポソーム、コンジュゲートなどのドラッグデリバリーシステムの改良は、融合タンパク質をベースとした治療薬の投与と効果を最適化する可能性を提供します。これらの技術は、融合タンパク質の安定性、バイオアベイラビリティ、特定の細胞や組織への標的送達を改善し、標的外影響を最小限に抑え、全体的な治療効果を高めることができます。ドラッグデリバリーの技術革新が進むにつれて、融合タンパク質の適用範囲が広がるだけでなく、患者のコンプライアンスや快適性も向上するため、融合タンパク質療法は幅広い病状に対してより魅力的なものとなり、市場の成長と技術革新を促進することになります。

安全性への懸念と副作用の可能性

他のバイオ医薬品と同様に、融合蛋白質にも副作用や予期せぬ結果をもたらすリスクがあります。このような治療法の安全性プロファイルを確保することは極めて重要であり、何らかの問題があれば、規制上の後退、社会的懐疑、市場の不確実性につながりかねないです。これらのリスクを軽減するためには、臨床試験中の融合タンパク質候補の厳密な評価とモニタリングが不可欠です。安全性の懸念に対処するには、継続的な調査、ファーマコビジランス、リスク管理戦略の開発が必要です。最終的には、良好なベネフィット対リスクの比率を維持することが、融合タンパク質治療が市場に受け入れられ、長期的に成功するために不可欠です。

COVID-19の影響：

COVID-19パンデミックは融合タンパク質市場に様々な影響を与えました。臨床試験やサプライチェーンが一時的に混乱した一方で、バイオ医薬品の研究開発の重要性が浮き彫りになっています。融合タンパク質は治療介入のための万能な候補であるため、COVID-19治療やワクチン開発の可能性に対する関心が高まっています。パンデミックはバイオテクノロジーの研究を加速させ、それによって間接的に融合タンパク質部門に利益をもたらしました。しかし、COVID-19関連治療に対する不確実性と注目は、一時的に他の病状から資源と注意をそらし、融合タンパク質市場の研究開発の全体的なペースに影響を与えました。

予測期間中、免疫グロブリン（Ig）融合セグメントは最大になる見込み

免疫グロブリン（Ig）融合セグメントは有利な成長が見込まれます。これらの人工タンパク質は、抗体の抗原特異的認識と目的の別のタンパク質やペプチドを組み合わせたものです。Ig融合タンパク質は、がん、自己免疫疾患、感染症など様々な疾患の標的治療薬として、バイオ医薬品に幅広く利用されています。さらに、特定のバイオマーカーの正確な検出を容易にする、診断学において不可欠なツールとしての役割も果たしています。Ig融合タンパク質は個別化医療の最前線に位置し、オーダーメイドの治療選択肢と革新的な研究手段を提供し、融合タンパク質市場の成長と開拓に大きく貢献しています。

予測期間中、生物学的技術分野のCAGRが最も高くなると予測される

生物学的技術分野は、予測期間中に最も速いCAGRの成長が見込まれます。遺伝子工学、組み換えDNA技術、タンパク質発現システムの進歩により、治療特性を向上させた複雑な融合タンパク質の作製が可能になっています。バイオテクノロジーのツールや技術は、特定の疾患や経路を標的とする融合タンパク質の精密な設計や改変を容易にしています。バイオテクノロジー企業はこの分野で継続的に技術革新を行っており、融合タンパク質療法の成長を牽引しています。さらに、バイオテクノロジーの進歩は、効率的な製造、品質管理、新規ドラッグデリバリー技術の開発に貢献し、融合タンパク質を現代のバイオ医薬品イノベーションの要としています。

最大のシェアを占める地域：

予測期間中、北米市場は先進的なヘルスケアインフラ、強固なバイオテクノロジー部門、重要な研究開発活動により、引き続き市場シェアの大半を占めると予想されます。特に米国とカナダは、融合タンパク質を用いた治療法の革新と臨床試験の最前線にあります。これらの国々には、バイオ医薬品の開発と商業化を奨励する、確立された規制の枠組みと支援政策があります。さらに、慢性疾患の有病率の増加、個別化医療の重視の高まり、ヘルスケア研究への多額の投資が、融合タンパク質市場における同地域の優位性に寄与しています。

CAGRが最も高い地域：

アジア太平洋地域はスパイスラム市場で重要な役割を担っており、予測期間中のCAGRが最も高いと予測されています。同地域の製薬・バイオテクノロジー産業の拡大と患者人口の多さは、大きなビジネスチャンスとなっています。アジア太平洋地域では研究開発への投資が増加しており、中国やインドなどの国々がバイオ医薬品生産の拠点となっています。さらに、慢性疾患の有病率は上昇傾向にあり、融合タンパク質を含む革新的な治療法の需要を牽引しています。アジア太平洋地域の市場成長の可能性、臨床試験、製造能力は、この地域の拡大するヘルスケア市場への参入を目指す世界のバイオ医薬品企業にとって重要な焦点となっています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の融合タンパク質市場：タイプ別

• 免疫グロブリン（Ig）融合タンパク質
• 副甲状腺ホルモン（PTH）融合タンパク質
• サイトカイン組換え融合タンパク質
• その他のタイプ

第6章 世界の融合タンパク質市場：用途別

• キメラタンパク質医薬品
• バイオテクノロジー
• 診断
• ドラッグデリバリー
• その他の用途

第7章 世界の融合タンパク質市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Abnova
• Roche
• Chimerigen
• Peprotech
• Amgen Science
• Astellas Pharma
• Bristol-Myers Squibb
• ProSpec
• Viventia
• Genzyme
• Ligand Pharmaceuticals
• Novus
• Regeneron
• Origene
• Absolute Antibody

List of Tables

• Table 1 Global Fusion Proteins Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 4 Global Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 5 Global Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 6 Global Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 7 Global Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 8 Global Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 9 Global Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 10 Global Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 11 Global Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 12 Global Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 13 North America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
• Table 14 North America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 15 North America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 16 North America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 17 North America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 18 North America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 19 North America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 20 North America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 21 North America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 22 North America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 23 North America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 24 North America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 25 Europe Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
• Table 26 Europe Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 27 Europe Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 28 Europe Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 29 Europe Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 30 Europe Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 31 Europe Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 32 Europe Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 33 Europe Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 34 Europe Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 35 Europe Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 36 Europe Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 37 Asia Pacific Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
• Table 38 Asia Pacific Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 39 Asia Pacific Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 40 Asia Pacific Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 41 Asia Pacific Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 42 Asia Pacific Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 43 Asia Pacific Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 44 Asia Pacific Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 45 Asia Pacific Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 46 Asia Pacific Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 47 Asia Pacific Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 48 Asia Pacific Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 49 South America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
• Table 50 South America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 51 South America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 52 South America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 53 South America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 54 South America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 55 South America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 56 South America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 57 South America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 58 South America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 59 South America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 60 South America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 Middle East & Africa Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
• Table 62 Middle East & Africa Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
• Table 63 Middle East & Africa Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
• Table 64 Middle East & Africa Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
• Table 65 Middle East & Africa Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
• Table 66 Middle East & Africa Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 67 Middle East & Africa Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
• Table 68 Middle East & Africa Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
• Table 69 Middle East & Africa Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
• Table 70 Middle East & Africa Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 71 Middle East & Africa Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 72 Middle East & Africa Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Fusion Proteins Market is accounted for $29.8 billion in 2023 and is expected to reach $45.4 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Fusion proteins are artificial proteins created by joining two or more genes that code for separate proteins. These hybrid proteins serve various purposes, such as in biotechnology and medicine. In biotechnology, fusion proteins are used to produce specific proteins in large quantities for research or therapeutic purposes. They can also be utilized as molecular tags for protein purification or as tools for studying protein interactions.

According to Globocan 2020, there were 19,292,789 new cases of cancer reported, and this number is expected to increase to 28,887,940 by 2040.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

With the growing digitization of content and distribution channels, there is a greater need to protect valuable intellectual property from cyber threats such as hacking, data breaches, and unauthorized distribution. DRM solutions offer robust encryption, access controls, and monitoring capabilities, making it harder for cybercriminals to compromise and steal sensitive content. As a result, industries like entertainment, publishing, and software development are increasingly adopting DRM technologies to safeguard their assets, ensuring content security and reducing the risk of revenue loss due to cyber attacks and piracy.

Restraint:

High development Costs

The research, development, and clinical testing required bringing fusion protein therapies to market demand substantial financial investment. These costs encompass preclinical studies, extensive clinical trials, regulatory compliance, and manufacturing infrastructure. High development expenses can be especially challenging for smaller biotech companies, potentially limiting their ability to innovate and compete. To overcome this restraint, collaboration, public-private partnerships, and funding initiatives are essential to support the research and development of fusion proteins. Additionally, cost-effective development strategies and efficient clinical trial design can help alleviate this financial burden, ultimately fostering the growth of this vital therapeutic sector.

Opportunity:

Improving drug delivery technologies

Enhanced drug delivery systems, such as nanoparticles, liposomes, and conjugates, offer the potential to optimize the administration and effectiveness of fusion protein-based therapies. These technologies can improve the stability, bioavailability, and targeted delivery of fusion proteins to specific cells or tissues, minimizing off-target effects and enhancing overall treatment outcomes. As drug delivery innovations continue to evolve, they not only expand the applicability of fusion proteins but also enhance patient compliance and comfort, making fusion protein therapies more attractive for a wide range of medical conditions and thus driving market growth and innovation.

Threat:

Safety concerns and potential side effects

Fusion proteins, like all biopharmaceuticals, can carry risks of adverse reactions or unintended consequences. Ensuring the safety profile of these therapies is crucial, as any issues can lead to regulatory setbacks, public skepticism, and market uncertainty. The rigorous evaluation and monitoring of fusion protein candidates during clinical trials are essential to mitigate these risks. Addressing safety concerns demands continuous research, pharmacovigilance, and the development of risk management strategies. Ultimately, maintaining a favorable benefit-to-risk ratio is imperative for the market acceptance and long-term success of fusion protein therapies.

COVID-19 Impact:

The COVID-19 pandemic has had mixed effects on the Fusion Proteins market. While it momentarily disrupted some clinical trials and supply chains, it also underscored the importance of biopharmaceutical research and development. Fusion proteins, being versatile candidates for therapeutic interventions, have seen increased interest in potential COVID-19 treatments and vaccine development. The pandemic has accelerated research in biotechnology, thereby indirectly benefiting the fusion proteins sector. However, the uncertainties and focus on COVID-19-related therapies temporarily diverted resources and attention from other medical conditions, impacting the overall pace of research and development in the Fusion Proteins market.

The immunoglobulin (Ig) fusion segment is expected to be the largest during the forecast period

The immunoglobulin (Ig) fusion segment is expected to have a lucrative growth. These engineered proteins combine an antibody's antigen-specific recognition with another protein or peptide of interest. They find extensive use in biopharmaceuticals, offering targeted therapies for a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. Additionally, they serve as indispensable tools in diagnostics, facilitating the precise detection of specific biomarkers. Ig Fusion Proteins are at the forefront of personalized medicine, providing tailored treatment options and innovative research avenues, contributing significantly to the growth and development of the Fusion Proteins market.

The biological technology segment is expected to have the highest CAGR during the forecast period

The biological technology segment is anticipated to witness the fastest CAGR growth during the forecast period. Advances in genetic engineering, recombinant DNA technology, and protein expression systems have enabled the creation of complex fusion proteins with enhanced therapeutic properties. Biotechnology tools and techniques facilitate the precise design and modification of fusion proteins to target specific diseases and pathways. Biotech companies are continuously innovating in this field, driving the growth of fusion protein therapies. Moreover, biotechnological advancements contribute to efficient manufacturing, quality control, and the development of novel drug delivery technologies, making fusion proteins a cornerstone of modern biopharmaceutical innovation.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share due to its advanced healthcare infrastructure, robust biotechnology sector, and significant research and development activities. The United States and Canada, in particular, have been at the forefront of innovation and clinical trials for fusion protein-based therapies. These nations have well-established regulatory frameworks and supportive policies that encourage the development and commercialization of biopharmaceuticals. Additionally, the increasing prevalence of chronic diseases, a growing emphasis on personalized medicine, and substantial investment in healthcare research contribute to the region's dominance in the Fusion Proteins market.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the spice rum market and is projected to have the highest CAGR over the forecast period. The region's expanding pharmaceutical and biotechnology industry, coupled with a large patient population, presents significant opportunities. Asia Pacific is witnessing increased investment in research and development, with countries like China and India becoming hubs for biopharmaceutical production. Furthermore, the prevalence of chronic diseases is on the rise, driving the demand for innovative therapies, including fusion proteins. Asia Pacific's potential for market growth, clinical trials, and manufacturing capabilities make it a key focus for global biopharmaceutical companies aiming to tap into the region's expanding healthcare market.

Key players in the market

Some of the key players in Fusion Proteins market include: Abnova, Roche, Chimerigen, Peprotech, Amgen Science, Astellas Pharma, Bristol-Myers Squibb, ProSpec, Viventia, Genzyme, Ligand Pharmaceuticals, Novus, Regeneron, Origene and Absolute Antibody.

Key Developments:

In August 2022, Amgen Inc. and Teneobio Inc. announced a deal in which Amgen would acquire Teneobio, which is a privately owned clinical-stage biotechnology firm focusing on a novel class of biologics known as Human Heavy-Chain Antibodies. Amgen's capabilities to develop advanced medicine in treating patients with severe diseases and commercialize best-in-class products will be strengthened by the acquisition of Teneobio.

In July 2022, Formation Biologics Inc., which is a protein engineering business specializing in biotherapeutics for cancer and fibrotic disorders was acquired by Bristol-Myers Squibb Company. Bristol-Myers Squibb acquired Forbius' TGF-beta program, including the lead experimental option, AVID200, as part of the acquisition. Primarily, Bristol-Myers Squibb intends to focus on AVID200 R&D in cancer detection, with the possibility of broadening its application to other therapeutic areas such as fibrosis.

Types Covered:

• Immunoglobulin (Ig) Fusion Protein
• Parathyroid Hormone (PTH) Fusion Protein
• Cytokines Recombinant Fusion Protein
• Other Types

Applications Covered:

• Chimeric Protein Drugs
• Biological Technology
• Diagnostics
• Drug Delivery
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Fusion Proteins Market, By Type

• 5.1 Introduction
• 5.2 Immunoglobulin (Ig) Fusion Protein
• 5.3 Parathyroid Hormone (PTH) Fusion Protein
• 5.4 Cytokines Recombinant Fusion Protein
• 5.5 Other Types

6 Global Fusion Proteins Market, By Application

• 6.1 Introduction
• 6.2 Chimeric Protein Drugs
• 6.3 Biological Technology
• 6.4 Diagnostics
• 6.5 Drug Delivery
• 6.6 Other Applications

7 Global Fusion Proteins Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Abnova
• 9.2 Roche
• 9.3 Chimerigen
• 9.4 Peprotech
• 9.5 Amgen Science
• 9.6 Astellas Pharma
• 9.7 Bristol-Myers Squibb
• 9.8 ProSpec
• 9.9 Viventia
• 9.10 Genzyme
• 9.11 Ligand Pharmaceuticals
• 9.12 Novus
• 9.13 Regeneron
• 9.14 Origene
• 9.15 Absolute Antibody